ArticleTheranostics2020
Detection of Lymph Node Metastases by Ultra-pH-Sensitive Polymeric Nanoparticles.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Porphyrin-lipid nanotheranostics for multimodal imaging of nodal disease in preclinical oral cancers.Theranostics · 2026Article
- A Multi-Threshold Micelle Improves Tumor Accumulation and STING Immunotherapy.Journal of the American Chemical Society · 2025Article
- Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Intraoperative diagnosis of early lymphatic metastasis using neodymium-based rare-earth NIR-II fluorescence nanoprobe.Nanoscale advances · 2023Article
- Multifunctional nanocarriers for targeted drug delivery and diagnostic applications of lymph nodes metastasis: a review of recent trends and future perspectives.Journal of nanobiotechnology · 2023Review
- Nanotechnology-Aided Advancement in Combating the Cancer Metastasis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Intraoperative molecular imaging: 3rd biennial clinical trials update.Journal of biomedical optics · 2023Review
- Nanoparticles for Lymph Node-Directed Delivery.Pharmaceutics · 2023Review
- Article
- Pericancerous lymph node imaging with indocyanine green-guided near-infrared fluorescence in radical esophagectomy: Protocol for a single-center, prospective, randomized controlled clinical trial.Thoracic cancer · 2022Article
- Nanotechnology-aided advancement in the combating of cancer metastasis.Cancer metastasis reviews · 2022Review
- Article
- Raman Nanotags-Guided Intraoperative Sentinel Lymph Nodes Precise Location with Minimal Invasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Innovations in lymph node targeting nanocarriers.Seminars in immunology · 2021Review
- Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities.Radiology. Imaging cancer · 2021Review
- Administration route governs the therapeutic efficacy, biodistribution and macrophage targeting of anti-inflammatory nanoparticles in the lung.Journal of nanobiotechnology · 2021Article
- Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.Accounts of chemical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Lymph node (LN) dissection followed by histological analysis is the current standard for diagnosis of LN metastasis but the method suffers from patient morbidity and low sensitivity of detection. Ultra-pH sensitive (UPS) nanoparticles show remarkable accuracy in the delineation of primary tumor margins for precision cancer surgery. Herein we investigate the effectiveness of UPS nanoparticles to detect cancer-involved LNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.